laboratory abnormalities defined as dose-limiting toxicity in subjects with metastatic non-squamous nonsmall cell lung cancer NSCLC treated with AMG 386 in combination with pemetrexed and carboplatin Part 2: To estimate the treatment effect of AMG 386 as measured by progression free survival PFS of AMG 386 versus AMG 386 placebo in combination with pemetrexed and carboplatin induction therapy followed by pemetrexed and AMG 386 or AMG 386 placebo as maintenance therapy in subjects with metastatic non-squamous NSCLC
Data and Resources
- A Phase 1b2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancerjson
laboratory abnormalities defined as dose-limiting toxicity in subjects with...
|Release Date|| |
|Public Access Level|| |